The Pharma Job From Hell: Low Salary to Fix Sinking Giant Teva
- Outgoing Teva CEO Vigodman was second-lowest paid in industry
- Teva shares plunged as Vigodman cut profit outlook by 25%
An employee works with sterile products during the manufacture of pharmaceuticals inside Teva's factory in Godollo, Hungary.
Photographer: Akos Stiller/BloombergThis article is for subscribers only.
The world’s biggest maker of generic drugs is looking for a new CEO to oversee one of the toughest turnaround jobs in the industry.
The only thing that probably won’t be big about the role is the pay: Teva Pharmaceutical Industries Ltd.’s outgoing chief executive officer, Erez Vigodman, earned $5.7 million in 2015, making him the second-lowest paid CEO among rivals tracked by Bloomberg with at least $20 billion market value.